Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.

Wall Street rebondit grâce à l'exemption de droits de douane sur les véhicules La Bourse de New York a terminé en hausse ...

CAMBRIDGE, MA— Moderna , Inc. (NASDAQ: MRNA) a récemment annoncé que son PDG, Stephane Bancel, a effectué des achats ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Investing.com -- Les actions de Moderna Inc. affichent une hausse de 8,6% en pré-marché suite à l’annonce que le PDG Stephane ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...

The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 ...

Last night, two purchases of Moderna’s stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel’s company, called Boston Biotech Ventures, bought 102,821 shares for an ...

Moderna shares experienced a significant surge in trading on Thursday, posting a 5.58% gain in European markets and an impressive jump of up to 16% on the NASDAQ. This remarkable performance was ...